YU46087B - Postupak za dobijanje analoga rebekamicina - Google Patents

Postupak za dobijanje analoga rebekamicina

Info

Publication number
YU46087B
YU46087B YU208687A YU208687A YU46087B YU 46087 B YU46087 B YU 46087B YU 208687 A YU208687 A YU 208687A YU 208687 A YU208687 A YU 208687A YU 46087 B YU46087 B YU 46087B
Authority
YU
Yugoslavia
Prior art keywords
alkyl
rebeccamycin
alkoxycarbonyl
carboxyl
mono
Prior art date
Application number
YU208687A
Other languages
English (en)
Other versions
YU208687A (en
Inventor
T. Kaneko
H.S. Wong
J.J. Utzig
Original Assignee
Bristol-Myers Company New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Company New York filed Critical Bristol-Myers Company New York
Publication of YU208687A publication Critical patent/YU208687A/xx
Publication of YU46087B publication Critical patent/YU46087B/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/044Pyrrole radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

formule: u kojoj su A6 i A13 odabrani iz grupe koja se sastoji od vodonika i grupe -(CH2)nNR1R2, pri cemu bar jedan od A6 i A13 predstavlja grupu -(CH2)nNR1R2; R1 i R2 su, svaki nezavisno, odabrani od vodonika, nesupstituisane ili supstituisane C1-6alkil grupe, aralkil grupe koja u alkil delu ima 1-3 ugljenikova atoma a u aril delu nesupstituisani fenil ili fenil supstituisan sa jednom od tri alkil, alkoksi, hidroksi, halogene, karboksilne, alkoksikarbonilne, amino, mono-i di-nizi- alkilamino grupe, kao i aril grupe koja je odabrana od nesupstituisanog fenila ili fenila supstituisanog sa jednom do tri alkil, alkoksi, hidroksi, halogena, amino, mono- i dialkilamino, nitro, karboksilne, alkoksikarbonilne i cijano grupe, pod uslovom da R1 i R2 ne predstavljaju oba aril; ili R1 i R2, kada se uzmu zajedno, mogu da predstavljaju -(CH2)4-ili -(CH2)2-R3-(CH2)2-, da bi zajedno sa azotovim atomom za koji su vezani gradili petoclani ili sestoclani prsten, pri cemu R3 predstavlja CH2, NH, O ili S; n predstavlja ceo broj sa vrednostima od 1 do 6; X je odabrano od H,F,Cl, Br, C1-3alkil, OH, karboksilne, alkoksikarbonilne ili alkoksi grupe, u kojima alkil deo ima 1-3 ugljenikova atoma, benziloksi, amino i mono- i dialkilamino; i R4 je vodonik ili CH3; kao i njihovih farmaceutski prihvatljivih adicionih soli sa kiselinama i baznih soli, oznacen t ime, sto rebekamicin, formule: ili njegov derivat, rastvoren u pogodnom inertnom rastvaracu, u inertnoj atmosferi, reaguje sa jakom bazom u kolicini dovoljnoj da se dobije reaktivni intermedijer odabran od anjona rebekamicina koji ima negativnu sarzu u polozaju 6, od anjona rebekamicina koji ima negativnu sarzu u polozaju 13 i od dianjona rebekamicina koji ima negativne sarze u polozajima 6 i 13; sto tako dobijeni reaktivni intermedijer reaguje sa aminoalkil jedinjenjem predstavljenim formulom: L-(CH2)n-NR1R2 u kojoj L predstavlja hemijsku odlazecu grupu, a n, R1 i R2 su kao sto je definisano gore; i sto se iz reakcione smese, nakon zavrsene reakcije, izoluje aminoalkilovani derivat rebekamicina.
YU208687A 1986-11-21 1987-11-18 Postupak za dobijanje analoga rebekamicina YU46087B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/933,428 US4785085A (en) 1986-11-21 1986-11-21 Rebeccamycin analogs

Publications (2)

Publication Number Publication Date
YU208687A YU208687A (en) 1988-10-31
YU46087B true YU46087B (sh) 1992-12-21

Family

ID=25463937

Family Applications (1)

Application Number Title Priority Date Filing Date
YU208687A YU46087B (sh) 1986-11-21 1987-11-18 Postupak za dobijanje analoga rebekamicina

Country Status (28)

Country Link
US (1) US4785085A (sh)
EP (1) EP0269025B1 (sh)
JP (1) JPS63198695A (sh)
KR (1) KR910000897B1 (sh)
CN (1) CN1019806B (sh)
AT (1) ATE84539T1 (sh)
AU (1) AU614068B2 (sh)
CA (1) CA1287349C (sh)
CS (1) CS265248B2 (sh)
CY (1) CY1701A (sh)
DE (1) DE3783577T2 (sh)
DK (1) DK165986C (sh)
EG (1) EG18409A (sh)
ES (1) ES2053510T3 (sh)
FI (1) FI86189C (sh)
GR (1) GR3006776T3 (sh)
HK (1) HK49093A (sh)
HU (1) HU201773B (sh)
IE (1) IE60595B1 (sh)
IL (1) IL84515A (sh)
MX (1) MX9202849A (sh)
MY (1) MY102722A (sh)
NO (1) NO167741C (sh)
NZ (1) NZ222544A (sh)
PT (1) PT86188B (sh)
SG (1) SG25193G (sh)
YU (1) YU46087B (sh)
ZA (1) ZA878714B (sh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 K−252誘導体
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
DE3835842A1 (de) * 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
US5015578A (en) * 1989-03-23 1991-05-14 Bristol-Myers Squibb Company BMY-41950 antitumor antibiotic
CA2015996C (en) * 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
US5496809A (en) * 1989-05-10 1996-03-05 Bristol-Myers Squibb Co Stable solutions of rebeccamycin analog
US5158938A (en) * 1990-03-06 1992-10-27 Bristol-Myers Squibb Company Rebeccamycin
EP0445736A1 (en) * 1990-03-06 1991-09-11 Bristol-Myers Squibb Company Rebeccamycin analog and pharmaceutical composition containing it
US5344823A (en) * 1990-03-06 1994-09-06 Bristol-Myers Squibb Company Antitumor antibiotic BMY-41219
IL97233A (en) * 1990-03-06 1995-03-30 Bristol Myers Squibb Co Analogs of rabamycin, their manufacture and pharmaceutical preparations containing them
US5478813A (en) * 1990-05-11 1995-12-26 Banyu Pharmaceutical Co., Ltd. Antitumor substance BE-13793C derivatives
ATE158298T1 (de) * 1990-05-11 1997-10-15 Banyu Pharma Co Ltd Be-13793c-derivat mit antitumorwirkung
US5437996A (en) * 1992-11-24 1995-08-01 Banyu Pharmaceutical Co., Ltd. Microtetraspora strain for preparation of indolopyrrolocarbazole derivatives
US5591842A (en) * 1991-11-29 1997-01-07 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
US5589365A (en) * 1991-11-29 1996-12-31 Banyu Pharmaceutical Co., Ltd. Process for producing glycosylated indolopyrrolocarbazole derivatives by culturing certain microorganisms
NZ245203A (en) * 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
ES2125976T3 (es) * 1992-03-20 1999-03-16 Wellcome Found Otros derivados de indol con accion antiviral.
JP3603322B2 (ja) * 1992-12-14 2004-12-22 萬有製薬株式会社 インドロピロロカルバゾール誘導体の製造法
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
DE69418978T2 (de) * 1993-12-07 1999-10-28 Eli Lilly And Co., Indianapolis Synthese von Bisindolylmaleimiden
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
PT657458E (pt) * 1993-12-07 2002-02-28 Lilly Co Eli Inibidores de proteina cinase c
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
CA2179650C (en) * 1993-12-23 2007-10-30 William Francis Heath, Jr. Bisindolemaleimides and their use as protein kinase c inhibitors
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5922860A (en) * 1994-05-09 1999-07-13 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
WO1995030682A1 (fr) * 1994-05-09 1995-11-16 Banyu Pharmaceutical Co., Ltd. Derive d'indolopyrolocarbazole antitumoral
US5804564A (en) * 1994-05-09 1998-09-08 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
DE69531686T2 (de) * 1994-06-13 2004-07-15 Banyu Pharmaceutical Co., Ltd. Glycosyltransferase kodierendes gen und seine verwendung
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
DE69505470T2 (de) * 1994-08-04 1999-05-12 F. Hoffmann-La Roche Ag, Basel Pyrrolocarbazol
AU6836696A (en) * 1995-09-05 1997-03-27 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
BR9710648A (pt) * 1996-03-20 1999-08-17 Lilly Co Eli S¡ntese de indolilmaleimidas
US5859261A (en) * 1997-03-20 1999-01-12 Eli Lilly And Company Synthesis of indolylmaleimides
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
US6653290B2 (en) * 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
WO2002077255A1 (en) 2001-03-22 2002-10-03 Bristol-Myers Squibb Company Topoisomerase i selective cytotoxic sugar derivatives of indolopyrrolocarbazoles
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
US20070042975A1 (en) * 2003-09-16 2007-02-22 Koji Yamada Novel indolopyrrolocarbazole derivative with antitumor activity
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(rap)-접합체 투여에 의한 간 질환의 치료
ES2326459B1 (es) 2008-04-08 2010-05-28 Universidad De Oviedo Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos.
PT2398500T (pt) 2009-02-20 2019-06-14 2 Bbb Medicines B V Sistema de entrega de medicamentos à base de glutationas
TWI556839B (zh) 2009-05-06 2016-11-11 研究室護膚股份有限公司 包含活性劑-磷酸鈣粒子複合物之皮膚遞送組成物及其使用方法
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CN102125578B (zh) * 2010-11-24 2013-03-27 河南师范大学 具有抗癌活性的蝴蝶霉素类似物及合成方法
CN102898489B (zh) * 2010-11-24 2014-04-02 河南师范大学 具有抗癌活性的蝴蝶霉素类似物及合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552842A (en) * 1983-01-28 1985-11-12 Bristol-Myers Company Process for producing rebeccamycin
US4487925A (en) * 1983-01-28 1984-12-11 Bristol-Myers Company Rebeccamycin and process for its preparation
US4524145A (en) * 1984-09-04 1985-06-18 Bristol-Myers Company 4'-Deschlororebeccamycin pharmaceutical composition and method of use
JPS62220196A (ja) * 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ucn―01

Also Published As

Publication number Publication date
HU201773B (en) 1990-12-28
IL84515A0 (en) 1988-04-29
NZ222544A (en) 1990-11-27
FI875091A0 (fi) 1987-11-18
US4785085A (en) 1988-11-15
MY102722A (en) 1992-09-30
DK612987D0 (da) 1987-11-20
FI875091A (fi) 1988-05-22
DK165986B (da) 1993-02-22
KR880006246A (ko) 1988-07-22
ATE84539T1 (de) 1993-01-15
HUT45543A (en) 1988-07-28
NO874857D0 (no) 1987-11-20
ES2053510T3 (es) 1994-08-01
NO167741B (no) 1991-08-26
EG18409A (en) 1993-02-28
FI86189B (fi) 1992-04-15
YU208687A (en) 1988-10-31
EP0269025A2 (en) 1988-06-01
NO167741C (no) 1991-12-04
CS265248B2 (en) 1989-10-13
CY1701A (en) 1994-01-14
IE873152L (en) 1988-05-21
DK612987A (da) 1988-05-22
EP0269025A3 (en) 1990-08-29
PT86188A (en) 1987-12-01
HK49093A (en) 1993-05-27
NO874857L (no) 1988-05-24
IE60595B1 (en) 1994-07-27
DE3783577D1 (de) 1993-02-25
CA1287349C (en) 1991-08-06
PT86188B (pt) 1990-11-07
DE3783577T2 (de) 1993-05-19
CS824987A2 (en) 1989-01-12
CN87107928A (zh) 1988-08-10
GR3006776T3 (sh) 1993-06-30
DK165986C (da) 1993-07-19
IL84515A (en) 1991-11-21
FI86189C (fi) 1992-07-27
ZA878714B (sh) 1988-05-20
KR910000897B1 (ko) 1991-02-12
EP0269025B1 (en) 1993-01-13
JPH05400B2 (sh) 1993-01-05
CN1019806B (zh) 1992-12-30
AU8114887A (en) 1988-05-26
JPS63198695A (ja) 1988-08-17
SG25193G (en) 1993-05-21
MX9202849A (es) 1992-06-30
AU614068B2 (en) 1991-08-22

Similar Documents

Publication Publication Date Title
YU46087B (sh) Postupak za dobijanje analoga rebekamicina
PT83843B (pt) Processo para a preparacao de promedicamentos de rapamicina
HUT59081A (en) Process for producing aryl- and heteroaryl-ethylene derivatives and pharmaceutical compositions containing them
ES8205771A1 (es) Un procedimiento para la obtencion de un derivado acilado sustituido de acido octahidro-1h-indol-2-carboxilico
HUT43568A (en) Process for preparing novel 2-pyridiyl-acetic acid derivatives and pharmaceutics comprising the same